97 related articles for article (PubMed ID: 30105948)
1. Intermediate-Risk Papillary Thyroid Cancer: Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy.
Llamas-Olier AE; Cuéllar DI; Buitrago G
Thyroid; 2018 Oct; 28(10):1311-1317. PubMed ID: 30105948
[TBL] [Abstract][Full Text] [Related]
2. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment.
Ywata de Carvalho A; Kohler HF; Ywata de Carvalho CCG; Vartanian JG; Kowalski LP
Arch Endocrinol Metab; 2024 Apr; 68():e220506. PubMed ID: 38578436
[TBL] [Abstract][Full Text] [Related]
3. Early Post-operative Stimulated Serum Thyroglobulin: Role in Preventing Unnecessary Radioactive Iodine Treatment in Low to Intermediate Risk Papillary Thyroid Cancer.
Sezer H; Yazıcı D; Terzioğlu T; Tezelman S; Canbaz HB; Yerlikaya A; Demirkol MO; Kapran Y; Çolakoğlu B; Çilingiroğlu EN; Alagöl F
Am Surg; 2023 Dec; 89(12):5996-6004. PubMed ID: 37309609
[TBL] [Abstract][Full Text] [Related]
4. Impact of radioiodine therapy on recurrence and survival outcomes in intermediate-risk papillary thyroid carcinoma -A systematic review and meta-analysis.
Chandekar KR; Satapathy S; Bal C
Clin Endocrinol (Oxf); 2024 Feb; 100(2):181-191. PubMed ID: 38050454
[TBL] [Abstract][Full Text] [Related]
5. Retrospective case-control study examining the relationship between recurrence-free survival and changes in pre- and post-radioiodine therapy serum thyroglobulin levels in patients with differentiated thyroid cancer.
Watanabe K; Igarashi T; Uchiyama M; Ishigaki T; Ojiri H
Jpn J Radiol; 2024 Apr; 42(4):391-397. PubMed ID: 38212512
[TBL] [Abstract][Full Text] [Related]
6. Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer.
Yu F; Li X; Ji Y; Tan J; Zhang G; Wang P; He Y; Wang R
Front Endocrinol (Lausanne); 2021; 12():743310. PubMed ID: 34858329
[TBL] [Abstract][Full Text] [Related]
7. Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes.
Simões-Pereira J; Saramago A; Rodrigues R; Pojo M; Pires C; Horta M; López-Presa D; Rito M; Cabrera R; Ferreira TC; Leite V; Cavaco BM
Endocrine; 2024 May; 84(2):625-634. PubMed ID: 38102497
[TBL] [Abstract][Full Text] [Related]
8. Impact of lymphovascular invasion on otherwise low-risk papillary thyroid carcinomas: a retrospective and observational study.
Puga FM; Al Ghuzlan A; Hartl DM; Bani MA; Moog S; Pani F; Breuskin I; Guerlain J; Faron M; Denadreis D; Baudin E; Hadoux J; Lamartina L
Endocrine; 2024 Jan; 83(1):150-159. PubMed ID: 37639174
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of adjuvant radioactive iodine after reoperation in patients with persistent or recurrent differentiated thyroid cancer: a systematic review.
Raghupathy J; Tan BKJ; Song HJJMD; Chia AZQ; Tan YZ; Yang SP; Parameswaran R
Langenbecks Arch Surg; 2023 Jan; 408(1):21. PubMed ID: 36635455
[TBL] [Abstract][Full Text] [Related]
10. Papillary thyroid carcinoma: the impact of histologic vascular invasion.
Fonseca L; Borges Duarte D; Brandão JR; Alves Pereira C; Amado A; Gouveia P; Couto Carvalho A; Borges F; Freitas C
Minerva Endocrinol (Torino); 2024 Mar; 49(1):69-75. PubMed ID: 36251020
[TBL] [Abstract][Full Text] [Related]
11. Basal or stimulated thyroglobulin in evaluating response to treatment in papillary thyroid carcinoma? A retrospective cohort study.
Barreto L; Ferreira DCG; Corrente JE; Soares CSP; Oliveira CC; Terra SA; Moriguchi SM; Koga KH; Tagliarini JV; da Silva Mazeto GMF
Hormones (Athens); 2024 Mar; 23(1):97-106. PubMed ID: 38015413
[TBL] [Abstract][Full Text] [Related]
12. Radioactive iodine administration is not associated with improved disease-specific survival in classic papillary thyroid carcinoma greater than 4 cm confined to the thyroid.
Lee-Saxton YJ; Palacardo F; Greenberg JA; Egan CE; Marshall TE; Tumati A; Beninato T; Zarnegar R; Fahey TJ; Finnerty BM
Surgery; 2024 Jan; 175(1):215-220. PubMed ID: 38563429
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and immune checkpoint status of radioiodine-refractory recurrent papillary thyroid carcinomas from Ukrainian Chornobyl Tissue Bank donors.
Bogdanova T; Rogounovitch TI; Zurnadzhy L; Mitsutake N; Tronko M; Ito M; Bolgov M; Chernyshov S; Gulevatyi S; Masiuk S; Yamashita S; Saenko VA
Front Endocrinol (Lausanne); 2023; 14():1343848. PubMed ID: 38260161
[TBL] [Abstract][Full Text] [Related]
14. Treatment strategies for low-risk papillary thyroid carcinoma: a position statement from the Thyroid Department of the Brazilian Society of Endocrinology and Metabolism (SBEM).
Ward LS; Scheffel RS; Hoff AO; Ferraz C; Vaisman F
Arch Endocrinol Metab; 2022 Sept 08; 66(4):522-532. PubMed ID: 36074944
[TBL] [Abstract][Full Text] [Related]
15. External beam radiation therapy for recurrent or residual thyroid cancer: What is the best treatment time and the best candidate for long-term local disease control?
Cavalcante LBCP; Treistman N; Gonzalez FMTT; Fernandes PIW; Alves Junior PAG; Andrade FA; Ferreira EN; Brito TF; Pane A; Corbo R; Erlich F; Bulzico DA; Vaisman F
Head Neck; 2024 Jun; 46(6):1340-1350. PubMed ID: 38445804
[TBL] [Abstract][Full Text] [Related]
16. Early Dynamic Risk Stratification Decreases Rate of Ablative and Adjuvant Radioiodine Use in ATA Low and Intermediate Risk Papillary Thyroid Cancer Patients.
Gorur SK; Ozbas S; Ilgan S
Sisli Etfal Hastan Tip Bul; 2023; 57(4):451-457. PubMed ID: 38268648
[TBL] [Abstract][Full Text] [Related]
17. Use of radioactive iodine for thyroid cancer.
Haymart MR; Banerjee M; Stewart AK; Koenig RJ; Birkmeyer JD; Griggs JJ
JAMA; 2011 Aug; 306(7):721-8. PubMed ID: 21846853
[TBL] [Abstract][Full Text] [Related]
18. Current practice in intermediate risk differentiated thyroid cancer - a review.
do Prado Padovani R; Duarte FB; Nascimento C
Rev Endocr Metab Disord; 2024 Feb; 25(1):95-108. PubMed ID: 37995023
[TBL] [Abstract][Full Text] [Related]
19. Wire-guided localization and surgical resection of non-palpable recurrent of thyroid carcinoma: A STROBE-compliant, retrospective cohort study.
Carrillo JF; Carrillo LC; Ramírez-Ortega MC; Pacheco-Bravo I; Ramos-Mayo A; Oñate-Ocaña LF
Eur J Surg Oncol; 2024 Jan; 50(1):107306. PubMed ID: 38048725
[TBL] [Abstract][Full Text] [Related]
20. A rare case of thyroid carcinosarcoma arising from recurrent papillary thyroid cancer: Case report and review of the literature.
Gao Y; Tang Y; Zhang X; Wu P
Oral Oncol; 2024 Mar; 150():106694. PubMed ID: 38262251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
